

Rassegne

Nerve growth factor in the psychiatric brain

Il fattore di crescita nervosa nelle patologie cerebrali psichiatriche

STEFANIA CIAFRÈ¹, GIAMPIERO FERRAGUTI², PAOLA TIRASSA³, ANGELA IANNITELLI⁴,
MASSIMO RALLI⁵, ANTONIO GRECO⁵, GEORGE N. CHALDAKOV⁶, PAMELA ROSSO², ELENA FICO²,
MARISA PATRIZIA MESSINA⁷, VALENTINA CARITO², LUIGI TARANI⁸, MAURO CECCANTI⁹,
MARCO FIORE^{2*}

*E-mail: marcofiore.roma@gmail.com

¹Institute of Translational Pharmacology, IFT-CNR, Institute of Cell Biology and Neurobiology, IBCN-CNR, Rome, Italy

²Department of Experimental Medicine, Sapienza University of Rome, Italy

³Institute of Biochemistry and Cell Biology, IBBC-CNR, Rome, Italy

⁴Department of Biotechnology and Applied Clinical Sciences, University of L'Aquila, Italy

⁵Department of Sense Organs, Sapienza University of Rome, Italy

⁶Department of Anatomy and Cell Biology, Medical University, Varna, Bulgaria

⁷Department of Gynecology, Obstetric, and Urology, Sapienza University of Rome, Italy

⁸Department of Pediatrics, Medical Faculty, Sapienza University of Rome, Italy

⁹Centro Riferimento Alcolologico Regione Lazio, ASL Roma 1, Rome, Italy

SUMMARY. The nerve growth factor (NGF) belongs to a family of proteins named neurotrophins, consisting of NGF, brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), NT-4/5 and NT-6. NGF regulates a large number of physiological mechanisms that result in neurotrophic, metabotropic and/or immunotrophic effects. Neurodegenerative diseases, including Alzheimer disease, psychiatric disorders (e.g. depression and schizophrenia) and brain parasitic infection have in common the effect of changing the brain levels of neurotrophins, in particular NGF. The contribution of both NGF and its receptor TrkA in such events and the recent promising results of NGF based therapies are here presented and discussed.

KEY WORDS: NGF, Alzheimer disease, depression, brain, parasite, alcohol, neurodegeneration.

RIASSUNTO. Il fattore di crescita nervosa (NGF) appartiene a una famiglia di proteine chiamate neurotrofine, costituita dall'NGF, il fattore neurotrofico di derivazione cerebrale (BDNF), la neurotrofina-3 (NT-3), NT-4/5 e NT-6. L'NGF regola un gran numero di meccanismi fisiologici che provocano effetti neurotrofici, metabotropici e/o immunotropici. Le malattie neurodegenerative, tra cui la malattia di Alzheimer, il danno indotto dall'alcol, i disturbi psichiatrici (per es., depressione e schizofrenia) e l'infezione parassitaria cerebrale hanno in comune l'effetto di modificare i livelli cerebrali di neurotrofine, in particolare l'NGF. Vengono qui presentati e discussi il contributo dell'NGF e del suo recettore TrkA in tali eventi e i recenti promettenti risultati delle terapie basate sull'NGF.

PAROLE CHIAVE: NGF, malattia di Alzheimer, depressione, cervello, parassita, alcol, neurodegenerazione.

INTRODUCTION

Nerve growth factor (NGF), firstly isolated in 1956, is a neuropeptide regulating the survival and proliferation of selected neurons¹ in central and peripheral nervous system. Actually, NGF and its comparative molecules collectively known as neurotrophins are well documented mediators of multiple biological events in health and disease²⁻⁴, varying their effects from that neurotrophic^{5,6} through immunotrophic^{7,8} to metabotropic^{9,10}. Thus, NGF is implicated in the pathogenesis of a large spectrum of neuronal diseases (Alzheimer's and other neurodegenerative diseases) and non-neuronal disorders (atherosclerosis, obesity, type 2 dia-

betes mellitus and other cardiometabolic disorders)^{8,10-14}. Particularly in the brain, NGF plays a key role in several diseases leading to cell death and/or neurodegeneration during development or aging¹⁵⁻²¹. NGF is synthesized as a 130 kD precursor (proNGF) that is a complex of three proteins: α -NGF, β -NGF and β -NGF the latter acting as a serine protease that cuts the subunit releasing the 26 kD mature NGF; this latter form is biologically active as a multifunctional signaling molecule^{8,22,23}. NGF binds two types of receptors: the low-affinity NGF receptor p75 (LNGFR/p75^{NTR}) and the tropomyosin-related kinase A (TrkA)^{22,24}. TrkA receptor binding produces the homodimerization of the receptor and the autophosphorylation of the tyrosine residue of the cyto-

Nerve growth factor in the psychiatric brain

plasmic tail. The site of the TrkA phosphorylation is a docking site for the Shc adaptor protein that is in turn phosphorylated beginning several intracellular pathways involved in cell survival^{22,25}. One of these involves the activation of the serine/threonine kinase Akt that develops, by the recruitment on TrkA receptor complex, the growth factor receptor bound protein 2 (Grb2) and of another docking protein, the Grb2-associated Binder1 (GAB1). This structure activates phosphatidylinositol-3 kinase (PI3K) that, in turn, activates Akt. Inhibiting or blocking the activity of PI3K or Akt may elicit the death of sympathetic neurons in culture even after NGF administration; instead, when both kinases are constitutively expressed, neuronal cells can survive without NGF^{26,27}. NGF is involved primarily in the growth, proliferation, and survival of sympathetic and sensory neurons undergoing apoptosis if NGF is missing²⁸⁻³⁰.

Another pathway of NGF mediated neuronal survival involves the mitogen-activated protein kinase (MAPK). This pathway leads to the activation of the membrane-associated G protein Ras that phosphorylates the serine/threonine kinase Raf. This phosphorylation activates the MAPK cascade regulating transcription²⁵. Both pathways give rise to phosphorylation of the cyclic AMP response element binding protein (CREB), a transcription factor that translocates into the nucleus controlling the expression of anti-apoptotic genes. NGF plays also a delicate role in the fine regulation of learning and memory abilities during development, adult life and aging by influencing synaptic plasticity, tissue growth and attrition in crucial areas of the limbic system^{4,31-35}. The present review amplifies and updates findings for the contribution of NGF in the pathogenesis and therapy of neuropsychiatric disorders, in which cognitive and memory disorders are prevalent³⁶⁻³⁸ (Figure 1).

BRAIN PLASTICITY, BEHAVIOR AND NGF

Growth factors regulating the pathways involved in normal brain development have a significant role in the pathophysiology of mental disorders including those with a neurodevelopmental origin. Significant changes in growth factors' levels were observed in patients and in animal models where altered levels of these proteins were found to induce psychiatric behavior^{34,39-46}. During the embryonic and post-natal stages, psychophysical stressors altering the environment can modify the standard brain development opening the way in the adulthood to psychopathologies such as depression, alcohol abuse and drug dependence, schizophrenia, anomalous social behavior⁴⁷⁻⁵², conditions that will require in adulthood, very important and expensive psychosocial behavioral to improve the life and abilities of patients with several mental disorders⁵³⁻⁵⁵. Neurotrophins, together with hypothalamic-pituitary-adrenal (HPA) axis, play a pivotal role in controlling brain plasticity and behavior, particularly in crucial periods during ontogenesis, when forming brain is extremely sensitive to external stimulations⁵⁶. In rat models, stress during pregnancy increases fetal and maternal plasma corticosterone causing hypothalamic-pituitary-adrenal (HPA) axis dysregulation and a prolonged elevation of plasma glucocorticoids in response to stressing events^{49,50}. Neurotransmitter activity and synaptic development are altered by increased activity of corticosterone and corticotrophin-releasing hormone (CRH) in the developing brain eliciting behavioral disturbances in adulthood. Indeed, rats exposed to gestational stress develop depressive-like behaviors and hyper-anxiety combined with the amygdala increase in CRH activity^{49,50}. Quite interestingly, changes in the HPA axis de-




Figure 1 (From left) NGF regulates social behavior in male mice; NGF stimulation upregulates DISC1-Fez1 complex promoting neurite outgrowth; NGF stimulation elicits APP/TrkA binding favoring the non amyloidogenic pathway.

scribed in prenatally stressed mammals were also described in humans with endogenous major depression⁵⁷⁻⁵⁹. Significantly, it has been proven that ectopic expression of Brain Derived Neurotrophic Factor (BDNF) *in vivo* increases CRH, whereas reduced expression of BDNF, or its receptor TrkB, decreases CRH expression and normal HPA functions⁶⁰. Also during early postnatal life, nervous system development is sensitive to stressing events, and this contributes to inter-individual differences in vulnerability to psychopathologies. During the postnatal development of CNS, the neural network undergoes deep rearrangements^{61,62} and is particularly susceptible to external stimuli. In this period, NGF and BDNF regulates brain plasticity for a better adaptation to the environment^{8,63}. For example, mice grown in a nest with caregiving mother show better social behaviors and skills if compared to mice raised in standard laboratory conditions. These socially enriched mice show higher levels of NGF and BDNF in the hippocampus and hypothalamus^{64,65}. In the mouse, NGF is secreted and produced also by the submaxillary salivary glands^{66,67}. Neurobehavioral studies have demonstrated that aggressive behavior in adult male CD-1 mice induces a remarkable release of NGF from salivary glands into the bloodstream. These findings demonstrated a link between the NGF serum concentration and the achieved status in the fighting were subordination almost double serum levels of NGF compared to dominant mice⁶⁸⁻⁷⁰. Other works have assessed the correlation between increased NGF levels and subordinate behavior^{6,71}. In male mice, NGF chronic administration decreased aggressive behavior⁷⁰. NGF release was also activated by psychosocial stress that depends on interspecific interactions while physical stressors may produce less evident effects^{64,65}. Intermale aggressive behavior increases the synthesis of NGF in the hypothalamus⁷² likely because the NGF levels depends on psychological stimuli associated with anxiety, fear, hormones and neurotransmitters release to integrate the neuroendocrine response and the behavior in order to confirm the physiological homeostasis^{6,8,73}.

ALCOHOL-INDUCED BRAIN CHANGES AND NGF

Numerous human studies have shown that binge or chronic alcohol consumption as well as alcohol drinking during gestation or lactation are a central inducing-cause of brain alterations⁷⁴ including mental retardation in adults, adolescents and children⁷⁵⁻⁸⁴. As for the alcohol consumption during pregnancy, the plethora of consequences in children induced by alcohol are described as Fetal Alcohol Spectrum Disorders⁸⁵⁻⁸⁸. It has been clearly shown that chronic or binge alcohol consumption as well as alcohol exposure during fetal development may significantly impair neurotrophic factors production in the brain also affecting the expression of their receptors⁸⁹⁻⁹⁶. NGF is probably the most important neurotrophin involved in ethanol-induced toxicity. Many brain studies have disclosed that NGF and its receptors are altered during prenatal/acute/chronic alcohol abuse⁹⁷⁻¹⁰². In particular, as previously revealed⁹⁷ alcohol inhibits the expression of endogenous extracellular signal-regulated kinase (ERK) and the phosphatidylinositol-3-kinase (PI3K)¹⁰³⁻¹⁰⁵. Furthermore, data evidenced several epigenetic roles of NGF and BDNF in regulating the serum levels of interleukin-6 (IL-6), of tumor necrosis factor- α (TNF- α) and the symptomatology of alcohol dependence¹⁰⁶⁻¹⁰⁸. In particular, it has been shown an elevation in NGF and IL-6 serum levels following alcohol consumption as well as an association between BDNF, TNF- α serum levels and the history of alcohol abuse, suggesting that changes in the methylation of neurotrophins genes may contribute to the development of alcohol dependence by affecting relevant downstream signalling cascades^{97,108}.

SCHIZOPHRENIA AND NGF

Data from human and animal models suggest a function of neurotrophins also in the vulnerability to stress-related neuropsychosis^{109,110}. Increasing literature evidences demon-




Figure 2 Alcohol alters brain levels of NGF and its receptors and impair MAPK/ERK and PIK3 pathways that control the expression of anti-apoptotic genes; EtOH alters methylation pathway of NGF and BDNF genes, that, in turn regulate serum levels of IL6 and TNF-alpha.

Nerve growth factor in the psychiatric brain

strate that in psychopathological conditions the constitutive levels of neurotrophins are disrupted in both brain and plasma. In schizophrenics without neuroleptic therapy, NGF plasma levels are lower if compared to healthy subjects⁴⁰. Haloperidol administration in human and mice drastically depletes NGF plasma levels¹¹¹ inducing sedation. By contrast, the atypical antipsychotics olanzapine, clozapine, and risperidone induced higher levels of plasmatic NGF compared to non-medicated first-episode psychotic patients¹¹². The crucial role played by NGF during cholinergic neurons development for regulating learning and memory could explain the vulnerability of the schizophrenic brain and the cognitive alterations observed in this disease; low levels of NGF may trigger consequent neurodevelopmental deficits. In schizophrenics, brain imaging studies evidenced modifications in selected brain areas such as prefrontal, temporal and anterior cingulum involved in affective-cognitive processes¹¹³⁻¹¹⁶. Furthermore, the post-mortem examination of schizophrenic brains disclosed a reduction of cell proliferation in the entorhinal cortex, prefrontal region and anterior cingulate that could elucidate the onset of the disease^{40,114}. In animal models, behavioral deficits associated with schizophrenic symptoms¹¹⁷ may be caused also by maternal exposure to risk factors such as alcohol drug abuse and obstetric complication¹¹⁸ that inhibit entorhinal and cortical neurogenesis⁵⁶.

Schizophrenia is a multifactorial mental disorder elicited by social, genetic and developmental factors^{119,120}. Disrupted-in-schizophrenia 1 (DISC1)^{121,122} which is expressed by neurons of the hippocampus, cerebral cortex, cerebellum and olfactory bulb in the rat brain is known to have a role in this disease^{123,124}. The coded protein binds other proteins including fasciculation and elongation protein zeta-1 (Fez1), which is involved in axonal outgrowth. DISC1-Fez1 molecular complex colocalizes in the growth cone of neurite proposing a function in the extension process also confirmed by the fact that these proteins are expressed in early ontogenic stages. In PC12 cells, neurodifferentiation following NGF stimulation was observed a drastic increase in Fez1 evidencing that NGF regulates the neurite outgrowth and extension upregulating DISC1-Fez1 complex¹²⁵. When DISC1 translocation prevents the complex being formed, neurite extension cannot occur leading to an immature brain development and supporting the hypothesis that schizophrenia is basically a neurodevelopmental disease¹²⁵.

NGF AND MAJOR DEPRESSION DISORDER

Major depression disorder (MDD) is one of most common brain disorders that implicates depression, fatigue, a decrease in concentration, scarce interest in normal daily activities and suicidal intentions¹²⁶. Several neurotrophins including NGF and BDNF are involved in MDD pathogenesis¹²⁷⁻¹²⁹. MDD patients display reduced serum NGF; the same diminution was observed in hippocampus mRNA and protein expression of NGF, BDNF and their receptors in post-mortem brain examination^{130,131}. A chemical mediator of the NGF decrease is Interferon-gamma (IFN- γ), as was demonstrated in IFN- γ knockout mice models that develop a depressive-like behavior, increased immobility and parallel reduction of NGF levels^{132,133}.

The administration of NGF in rats reduces the expression of the cholinergic gene CHRNA5 and prokineticin receptor1 (PROKR1) mimicking the effects of fluoxetine and amitriptyline therapy. The improvement of the depression-like behavior is achieved by modulating the expression of several genes in the amygdala and hippocampus¹³⁴.

NGF AND ALZHEIMER DISEASE

Alzheimer disease (AD) is the most common type of dementia in the old age. AD is characterized by early alterations of synaptic proteins and synaptic functions with the formation of abnormal tau and amyloid proteins. After the discharge in the intracellular space of these abnormal proteins starts the massive deposition of senile plaques (SP) of the β -amyloid (A β) peptide and the aggregations of neurofibrillary tangles (NTF) originating from the hyperphosphorylated tau protein. According to the literature, during the progression of the disease, a serious and progressive memory deficit associated with a massive neuronal loss and a total deterioration of the brain homeostasis were observed¹³⁵⁻¹³⁷. The basal forebrain cholinergic neurons (BFCN) innervating the hippocampus and the cerebral cortex, brain areas controlling memory and attention are quite susceptible to the AD and the first to be involved^{138,139}.

In the pathophysiological mechanisms of AD, neurotrophic factors play a fundamental and protective role. Neurotrophins control plasticity, differentiation, pruning and survival of the BFCN and the signaling of these peptides is extremely altered in the course of the disorder¹⁴⁰. NGF is most studied neurotrophin for its role in AD development^{140,141}.

NGF signaling in BFCN involves three types of receptors: the high-affinity tropomyosin-related kinase A (TrkA), the low-affinity p75^{NTR} neurotrophin receptor (p75^{NTR}) and sortilin. NGF binding to its receptor TrkA activates the pathway signaling of cell survival, while in the presence of minor levels of NGF and/or TrkA the precursor form of NGF (pro-NGF) binds to the low-affinity p75 receptor and/or to sortilin determining an apoptotic signal leading to neurodegeneration^{142,143}.

Indeed, NGF release by cortical and hippocampal neurons is involved in the processing of amyloid precursor protein (APP) to produce the soluble and neuroprotective APP known also to be a strong inhibitor of the enzyme β -secretase 1 (BACE1) that regulates APP amyloidogenic cleavage¹⁴⁴. Recent studies in cellular and animal models have demonstrated the protective role of NGF against AD induced neurodegeneration. Moreover, there is strong evidence that the changes in NGF signaling is one of the earliest events in AD beginning¹⁴⁵. In a cellular model such as the primary hippocampal neurons, NGF removal generates an Alzheimer's like molecular condition with the development of A β -amyloid plaques and aggregations of neurofibrillary tangles¹⁴⁶. Also, an antibody pointed to NGF induces similar phenotypic effects and neuronal deficits in the AD11 mouse model of AD¹⁴⁷. The neuroprotective role of NGF observed *in vivo* and *in vitro* is exerted by the regulation of APP processing^{144,148}.

NGF stimulation of primary cholinergic septal neurons elicits the binding of TrkA receptor to APP. This binding

blocks the APP phosphorylation at the threonine 668 (T668) residue in the cytosolic tail of the protein. T668 phosphorylation is an APP post-translational modification inducing APP cleavage by the enzyme BACE1 that controls the amyloidogenic pathway of maturation¹⁴⁴.

During the development of AD, NGF deficit is associated with an increased amyloid generation, initial synaptic alteration as observed in mild cognitive impairments and early AD. The newly generated amyloid inhibits the endocytosis of the NGF/TrkA complex and this negative feedback loop marks the AD beginning¹³⁵.

In rat models of aging, increased levels of pro-NGF and p75NTR in the hippocampus and prefrontal cortex are associated with a deficit in spatial learning and memory¹⁴⁹. An elevation in pro-NGF levels was also discovered in mild cognitive impairment and AD patients and during the examination of postmortem AD brain¹⁴⁵. The alteration of the NGF signaling is an early event during the progression of the AD as disclosed by studies on animal and cellular models¹⁵⁰. In animal models, as aged rats, the blocking of NGF/TrkA signaling induces a serious deficit in cholinergic function^{151,152}. In animal models of AD, the perturbation of NGF signaling leads to a general loss of central cholinergic activities¹⁵³. The effect of the imbalance in NGF/TrkA signaling leads to a pathological APP processing¹⁴⁶. In transgenic mice lacking APP/TrkA interaction, a severe degeneration of cholinergic neurons and cognitive deficits were described¹⁵⁴. These studies support the hypothesis of the *neurotrophic model* of AD development. Indeed, the reduction of NGF level and the increase in pro-NGF would activate the synaptic failure and the abnormal amyloid and tau deposition creating a neurodegenerative cascade^{27,155}.

New pieces of evidence corroborate the relationship between NGF and APP processing based on a physical interaction between APP and NGF receptors¹⁵⁰. The APP juxta-membrane region containing the β and β -secretase cutting sites and matches the first 16 aa of A peptide is sufficient for the interaction with TrkA and the binding to p75NTR¹⁵⁶. APP and TrkA proteins localize in the plasma membrane, endoplasmic reticulum (ER), Golgi and endocytic vesicles where the peptides form homodimers¹⁵⁰.

In primary septal neurons, NGF treatment elevates APP/TrkA complexes in ER and Golgi without increasing proteins level probably because NGF disrupts this association through the control of the APP phosphorylation^{148,150}. NGF withdrawal induces a decrease in APP/TrkA complexes and the same pattern is observed with cell death inducers such as A peptide and rapamycin. Furthermore, NGF, supporting APP/TrkA complexes, inhibits the APP/APP homodimers that are more prone to amyloidogenic processing carried out by β - and γ -secretase^{148,150}.

The APP post-translational alterations are crucial for the physiological or amyloidogenic pathways¹⁵⁷. The phosphorylation of the threonine residue 668 (T668) is related to amyloid production, synaptic deficits and apoptosis^{158,159}. This phosphorylation inhibits APP/TrkA binding and elevates A β production in cholinergic neurons *in vivo* and *in vitro*. A recent finding has shown that NGF can reduce APP T668 level in cultured BFCN. It is also possible that the detachment of APP from TrkA is due to changes in the conformation of APP upon its phosphorylation¹⁴⁸.

In the physiological anti-amyloidogenic pathway, binding

of NGF to TrkA elicits TrkA phosphorylation and TrkA docking of the signaling adaptor SH2 containing sequence C (ShcC). Activated ShcC blocks c-Jun N-terminal kinase (JNK), a ser/thr APP kinase, preventing the APP phosphorylation at threonine residue 668 (T668). Since TrkA can bind only APP molecules not phosphorylated at T668, the NGF decrease of APP p668 levels arouses ATP-TrkA binding, and the TrkA mediated trafficking of APP to the plasma membrane and Golgi apparatus and the preferential cleavage of APP by the neuronal β -secretases ADAM10-17. Contrariwise, the reduced availability of mature NGF and/or the reduced expression levels of TrkA result in pre-apoptotic signals that stimulate JNK, increase APP pT668 and disturb APP-TrkA interaction favoring the β -secretase 1 amyloidogenic pathway¹⁴⁸.

Beneficial role of NGF on cholinergic neurons is carried out downregulating T668 phosphorylation, stimulating APP/TrkA binding and trafficking the complex to subcellular compartments, as Golgi complex, that is depleted of the amyloidogenic enzyme like BACE1. Tau pathology is also implicated in non-Alzheimer disorder pathophysiology (suspected non-Alzheimer disease pathophysiology - SNAP). In AD, many studies have demonstrated a synergism between tangles and plaques, with abnormal tau that enhances A β toxicity and *vice-versa*^{160,161}.

NGF can control the steady-state levels and the post-translational maturation of tau that is cleavage, ubiquitination, and phosphorylation^{162,163}. NGF withdrawal brings to tau hyperphosphorylation and to abnormal cleavage of the N terminal fragment of the protein lacking the microtubule-binding domain. The same tau fragment was also observed in animal AD models with impaired NGF signaling^{162,164}.

NGF IN AUTISM SPECTRUM DISORDER

Autism Spectrum Disorder (ASD) includes deficits in social communication and repetitive behavioral patterns. Genetic perturbations play a critical role in ASD with hundreds of genes associated with it. However, such aberrations do not converge in a common molecular pathway. Genetic investigations and behavioral observations show the overlapping of ASD with other psychiatric diseases, such as bipolar disorder, schizophrenia, and Attention Deficit and Hyperactivity Disorder (ADHD)^{165,166}. Investigating differential alternative splicing (DAS) in the blood of 2-4 years old boys with a diagnosis of ASD, it was disclosed significant DAS changes in several genes of NGF receptors and signaling if compared to controls¹⁶⁷. In another study, Lu et al. showed several NGF single-nucleotide polymorphism associated with deficits in nonverbal communication, one of the main autistic trait¹⁶⁸.

NGF AND BRAIN PARASITOSIS

The role of NGF in parasitic disorders is not yet clearly recognized but some information emerged from investigations on *Trypanosoma cruzi* and *Schistosoma mansoni* brain neuroinflammation.

Chagas disease or American trypanosomiasis is a tropical parasitic disorder caused by the protist *Trypanosoma cruzi*

Nerve growth factor in the psychiatric brain

spread to humans and mammals by the insects “kissing bugs” of the subfamily Triatominae^{169,170}. During the early phase of the disease, symptoms are not present or are mild with headache, fever and swollen lymph nodes. Only the 40% of people develop severe symptoms of the disorder after 30-40 years from the infection. Symptoms may include heart failure due to enlargement of heart ventricles, or enlarged esophagus or colon (megaesophagus or megacolon). This disease affects about 6,6 million people mostly in Central America and Mexico¹⁷¹.

Trypanosoma cruzi releases the NGF mimetic neurotrophin called PDNF (parasite-derived neurotrophic factor), a membrane-bound neuraminidase/trans-sialidase that can bind TrkA but not p75^{NTR}^{5,172}. *Trypanosoma* infection in the CNS is usually asymptomatic and neuronal examination has revealed some sort of neuroprotection and neurons preservation even near foci of inflammatory cells or parasite nest¹⁷³. Neuroprotection and neuroregeneration were also discovered in animals with chronic or acute infection¹⁷⁴⁻¹⁷⁷. Signs of sprouting of sympathetic and parasympathetic nerve fibers were observed in the heart and colon with elevated levels of several neurotransmitters^{178,179}. These findings have shown that *Trypanosoma cruzi* PDNF is a functional simulator of NGF that can bind TrkA, can produce TrkA autophosphorylation and can trigger PI3K/Akt and MAPK-Erk1/2 signaling eliciting cell survival and neurite outgrowth. Quite interestingly, the inability of binding p75^{NTR} inhibits the cell-death signaling pathway^{180,181}. From an evolutionary and adaptive point of view, given the critical role of TrkA in neuronal maintenance, the parasitic invader utilizes TrkA to reduce tissue damage, to stimulate protective mechanisms and tissue repair maximizing host-parasite equilibrium in order to prolong parasitism. This mechanism could reveal a general and unexpected model of host-parasite interaction¹⁸⁰.

Neuroschistosomiasis refers to the *Schistosoma mansoni* infection of the central nervous system and depends basically on the presence of parasite eggs in the nervous tissue and on the host immune response. After eggs deposition, the mature embryo secretes and excretes antigenic and immunogenic mediators that start the granulomatous reaction^{182,183}. A large number of eggs and granulomas in CNS areas disrupts adjacent tissues by the inflammatory reaction and the mass effect¹⁸²⁻¹⁸⁶. In mice infected that manifest granulomas in several CNS areas it was found an increase in NGF levels in the cortex, hypothalamus, and brain stem with paw hyperalgesia^{187,188}. This murine model of chronic infection suggests that the neuropathological and sensory deficits observed in human infection are associated with abnormal NGF levels and/or activity in peripheral and central nervous systems caused by the local growth of granulomas^{67,189-195}.

NGF-based therapy

The neuroprotective action of NGF in animal models of neurodegenerative disease justified the beginning of clinical trials of NGF therapy in humans for several brain diseases including AD, schizophrenia^{196,197}.

Encouraging results were disclosed in the basal forebrain for individuals with implanted connective cells engineered to synthesize and secrete NGF. In these studies, enhanced cell size and new neural fibers were observed. Furthermore, cells

showing signs of pathology and protein clumps inside the cell body maintained a healthy size, activated prosurvival signaling and manifested stress resistance¹⁹⁸. To potentiate the NGF expression, modified viruses containing the NGF gene were directly injected in the basal forebrain^{198,199}. The protective role of NGF and its progressive decrease in AD is the rationale of the NGF therapy in which the administration of exogenous NGF could counteract the basal forebrain neurodegeneration²⁰⁰. First promising results were obtained in rodents where intracerebral NGF infusion was neuroprotective for cholinergic neuronal cells. Also in AD models like APP/PSI transgenic mouse, the less invasive treatment as ocular or nasal NGF administration decreased beta-amyloid deposition²⁰¹. In AD patients, NGF phase I gene therapy has shown axonal sprouting without side effects²⁰¹.

Abnormalities in NGF levels or signaling and the resulting impairments in neuroplasticity and cognitive abilities were also observed in psychiatric disorders such as bipolar disorders, schizophrenia, alcohol use disorders, major depression and autism. In schizophrenic patients treated with atypical antipsychotic drugs, NGF levels increased leading to a reduction of negative symptoms^{152,202}. In bipolar disorders, NGF decreases during the parossistic state but may be rescued by lithium administration by potentiating NGF concentration in the frontal cortex, hippocampus, and amygdala^{203,204}. In children with Rett syndrome, a disorder causing a delay in development and cognitive abilities resembling autism, therapies with NGF-like activity drugs may improve motor and cortical functions by also potentiating social interactions²⁰⁵.

NGF AS CLINICAL BIOMARKER OF PROGNOSIS AND DIAGNOSIS OF PSYCHIATRIC DISORDERS

Variations in the serum NGF concentrations have been associated with the pathogenesis and clinical symptoms of several psychiatric disruptions, such as: anxiety disease, mood disorders, schizophrenia, Alzheimer and others. Indeed, fluctuations in the serum levels of NGF and other growth factors are usually connected to the clinical severity and progression of mental illnesses⁴⁶. Several experimental evidences clearly demonstrate that the serum analysis as biomarkers of neurotrophins, including NGF, could be quite useful to early disclose the onset of several psychiatric disorders⁴⁶. The working hypothesis was based on the fact that the combined investigation of different neurotrophins could be utilized to establish whether or not such neuropeptides as biomarkers of psychiatric disorders or biomarkers of some cognitive, emotional and social deficits⁴⁶. Available data in the literature^{19,206,207} clearly stress the point that neurotrophins and other growth factors are *i*) involved in the pathophysiology of psychiatric pathologies with neurodevelopmental origin; *ii*) in animal models selected changes in the serum presence of neurotrophins and other growth factors may elicit psychiatric-like behaviors; *iii*) people affected by neuropsychiatric disorders may display significant modifications in certain neurotrophins and/or other growth factors; *iv*) disruptions in the blood levels of neurotrophins and/or other growth factors may be associated with the severity of the brain disease, changes in the behavior, poor social abilities, and cognitive performance decline. In particular, peripheral changes in

neurotrophins as NGF and/or BDNF resulted connected with functional impairments in cognitive and emotional processing whereas peripheral modifications in other growth factors as EGF, VEGF and FGF demonstrated subtle roles of these biomarkers in motor processing⁴⁶. However, as suggested by different researchers, at the present time do not exist specific and reliable biomarkers for each psychiatric disorder, but a combined screening of biomarkers appears the only alternative to improve the early diagnosis and clinical follow-up of psychiatric individuals⁴⁶.

CONCLUSIONS

Many years of research have recognized the important trophic and homeostatic role of NGF that exerts its modulatory functions on endocrine, nervous, adipose and immune system activities. Future studies, through an extended knowledge of the molecular mechanisms of action of this small and versatile peptide, will help to develop effective brain therapeutic strategies for many clinical sectors including those involving neurodegeneration, neuroinflammation and neuroendocrinology^{2,20,23,180,181}.

Conflicts of interests: authors do declare no conflicts of interest.

Acknowledgements: authors do thank Sapienza Università di Roma, Italy, and IBCN-CNR, Rome, Italy.

REFERENCES

1. Levi-Montalcini R. The nerve growth factor 35 years later. *Science* 1987; 237: 1154-62.
2. Rosso P, De Nicolò S, Carito V, et al. Ocular nerve growth factor administration modulates brain-derived neurotrophic factor signaling in prefrontal cortex of healthy and diabetic rats. *CNS Neurosci Ther* 2017; 23: 198-208.
3. Tirassa P, Rosso P, Iannitelli A. Ocular nerve growth factor (NGF) and NGF eye drop application as paradigms to investigate NGF neuroprotective and reparative actions. *Methods Mol Biol* 2018; 1727: 19-38.
4. Ciafrè S, Carito V, Ferraguti G, et al. Nerve growth factor in brain diseases. *Biomed Rev* 2018; 29: 1-16.
5. Sofroniew MV, Howe CL, Mobley WC. Nerve growth factor signaling, neuroprotection, and neural repair. *Annu Rev Neurosci* 2001; 24: 1217-81.
6. Aloe L, Alleva E, Fiore M. Stress and nerve growth factor: findings in animal models and humans. *Pharmacol Biochem Behav* 2002; 73: 159-66.
7. Chaldakov GN, Fiore M, Tonchev AB, Aloe L. Neuroadipology: a novel component of neuroendocrinology. *Cell Biol Int* 2010; 34: 1051-3.
8. Fiore M, Chaldakov GN, Aloe L. Nerve growth factor as a signaling molecule for nerve cells and also for the neuroendocrine-immune systems. *Rev Neurosci* 2009; 20: 133-45.
9. Chaldakov GN, Fiore M, Stankulov IS, et al. Neurotrophin presence in human coronary atherosclerosis and metabolic syndrome: a role for NGF and BDNF in cardiovascular disease? *Prog Brain Res* 2004; 146: 279-89.
10. Chaldakov GN, Fiore M, Ghenev PI, Stankulov IS, Aloe L. Atherosclerotic lesions: possible interactive involvement of intima, adventitia and associated adipose tissue. *Int Med J* 2000; 7: 43-9.
11. Tore F, Tonchev A, Fiore M, et al. From adipose tissue protein secretion to adipopharmacology of disease. *Immunol Endocr Metab Agents Med Chem* 2007; 7: 149-55.
12. Chaldakov GN, Beltovsky J, Ghenev PI, et al. Adipoparacrinology – vascular periadventitial adipose tissue (tunica adiposa) as an example. *Cell Biol Int* 2012; 36: 327-30.
13. Chaldakov GN, Fiore M, Tonchev A, et al. Homo obesus: a metatrophin-deficient species. *Pharmacology and nutrition insight. Curr Pharm Des* 2007; 13: 2176-9.
14. Chaldakov GN, Fiore M, Rančić G, et al. Rethinking vascular wall: periadventitial adipose tissue (tunica adiposa). *Obesity and Metabolism* 2010; 6: 46-9.
15. Fiore M, Triaca V, Amendola T, Tirassa P, Aloe L. Brain NGF and EGF administration improves passive avoidance response and stimulates brain precursor cells in aged male mice. *Physiol Behav* 2002; 77: 437-43.
16. Greco A, Ralli M, De Virgilio A, Inghilleri M, Fusconi M, de Vincentiis M. Letter to the Editor: Autoimmune pathogenic mechanisms in Huntington's disease. *Autoimmun Rev* 2018; 17: 942-3.
17. Skaper SD. Nerve growth factor: a neuroimmune crosstalk mediator for all seasons. *Immunology* 2017; 151: 1-15.
18. Aygun N. Biological and genetic features of neuroblastoma and their clinical importance. *Curr Pediatr Rev* 2018; 14: 73-90.
19. Allen SJ, Watson JJ, Shoemark DK, Barua NU, Patel NK. GDNF, NGF and BDNF as therapeutic options for neurodegeneration. *Pharmacol Ther* 2013; 138: 155-75.
20. Iulita MF, Caraci F, Cuello AC. A link between nerve growth factor metabolic deregulation and amyloid-beta-driven inflammation in down syndrome. *CNS Neurol Disord Drug Targets* 2016; 15: 434-47.
21. Greco A, Ralli M, Inghilleri M, De Virgilio A, Gallo A, de Vincentiis M. Letter to the Editor: Autoimmune pathogenic mechanisms in Amyotrophic Lateral Sclerosis. *Autoimmun Rev* 2018; 17: 530-1.
22. Kaplan DR, Martin-Zanca D, Parada LF. Tyrosine phosphorylation and tyrosine kinase activity of the trk proto-oncogene product induced by NGF. *Nature* 1991; 350: 158-60.
23. Donovan MJ, Miranda RC, Kraemer R, et al. Neurotrophin and neurotrophin receptors in vascular smooth muscle cells. Regulation of expression in response to injury. *Am J Pathol* 1995; 147: 309-24.
24. Chao MV. Trophic factors: an evolutionary cul-de-sac or door into higher neuronal function? *J Neurosci Res* 2000; 59: 353-5.
25. Sanes DH, Reh TA, Harris WA. Development of the nervous system. Amsterdam: Elsevier, 2005.
26. Yano H, Chao MV. Neurotrophin receptor structure and interactions. *Pharm Acta Helv* 2000; 74: 253-60.
27. Niewiadomska G, Mietelska-Porowska A, Mazurkiewicz M. The cholinergic system, nerve growth factor and the cytoskeleton. *Behav Brain Res* 2011; 221: 515-26.
28. Carito V, Venditti A, Bianco A, et al. Effects of olive leaf polyphenols on male mouse brain NGF, BDNF and their receptors TrkA, TrkB and p75. *Nat Prod Res* 2014; 28: 1970-84.
29. De Nicolò S, Tarani L, Ceccanti M, et al. Effects of olive polyphenols administration on nerve growth factor and brain-derived neurotrophic factor in the mouse brain. *Nutrition* 2013; 29: 681-7.
30. Freeman RS, Burch RL, Crowder RJ, et al. NGF deprivation-induced gene expression: after ten years, where do we stand? *Prog Brain Res* 2004; 146: 111-26.
31. Manni L, Aloe L, Fiore M. Changes in cognition induced by social isolation in the mouse are restored by electro-acupuncture. *Physiol Behav* 2009; 98: 537-42.
32. Amendola T, Fiore M, Aloe L. Postnatal changes in nerve growth factor and brain derived neurotrophic factor levels in the retina, visual cortex, and geniculate nucleus in rats with retinitis pigmentosa. *Neurosci Lett* 2003; 345: 37-40.

Nerve growth factor in the psychiatric brain

33. Fiore M, Angelucci F, Alleva E, Branchi I, Probert L, Aloe L. Learning performances, brain NGF distribution and NPY levels in transgenic mice expressing TNF- α . *Behav Brain Res* 2000; 112: 165-75.
34. Fiore M, Talamini L, Angelucci F, Koch T, Aloe L, Korf J. Prenatal methylazoxymethanol acetate alters behavior and brain NGF levels in young rats: a possible correlation with the development of schizophrenia-like deficits. *Neuropharmacology* 1999; 38: 857-69.
35. Aloe L, Properzi F, Probert L, et al. Learning abilities, NGF and BDNF brain levels in two lines of TNF- α transgenic mice, one characterized by neurological disorders, the other phenotypically normal. *Brain Res* 1999; 840: 125-37.
36. Santarelli V, Marucci C, Collazzoni A, et al. Could the severity of symptoms of schizophrenia affect ability of self-appraisal of cognitive deficits in patients with schizophrenia? Lack of insight as a mediator between the two domains. *Eur Arch Psychiatry Clin Neurosci* 2019; Nov 13 [Epub ahead of print].
37. Bucci P, Galderisi S, Mucci A, et al. Premorbid academic and social functioning in patients with schizophrenia and its associations with negative symptoms and cognition. *Acta Psychiatr Scand* 2018; 138: 253-66.
38. Mazza M, Pollice R, Pacitti F, et al. New evidence in theory of mind deficits in subjects with chronic schizophrenia and first episode: Correlation with symptoms, neurocognition and social function. *Riv Psichiatr* 2012; 47: 327-36.
39. Iannitelli A, Quartini A, Tirassa P, Bersani G. Schizophrenia and neurogenesis: a stem cell approach. *Neurosci Biobehav Rev* 2017; 80: 414-42.
40. Fiore M, Angelucci F, Aloe L, Iannitelli A, Korf J. Nerve growth factor and brain-derived neurotrophic factor in schizophrenia and depression: findings in humans, and animal models. *Curr Neuropharmacol* 2005; 1: 109-23.
41. Fiore M, Korf J, Antonelli A, Talamini L, Aloe L. Long-lasting effects of prenatal MAM treatment on water maze performance in rats: associations with altered brain development and neurotrophin levels. *Neurotoxicol Teratol* 2002; 24: 179-91.
42. Fiore M, Aloe L, Westenbroek C, Amendola T, Antonelli A, Korf J. Bromodeoxyuridine and methylazoxymethanol exposure during brain development affects behavior in rats: consideration for a role of nerve growth factor and brain derived neurotrophic factor. *Neurosci Lett* 2001; 309: 113-6.
43. Di Fausto V, Fiore M, Aloe L. Exposure in fetus of methylazoxymethanol in the rat alters brain neurotrophins' levels and brain cells' proliferation. *Neurotoxicol Teratol* 2007; 29: 273-81.
44. Fiore M, Di Fausto V, Iannitelli A, Aloe L. Clozapine or haloperidol in rats prenatally exposed to methylazoxymethanol, a compound inducing entorhinal-hippocampal deficits, alter brain and blood neurotrophins' concentrations. *Ann Ist Super Sanita* 2008; 44: 167-77.
45. Fiore M, Korf J, Angelucci F, Talamini L, Aloe L. Prenatal exposure to methylazoxymethanol acetate in the rat alters neurotrophin levels and behavior: considerations for neurodevelopmental diseases. *Physiol Behav* 2000; 71: 57-67.
46. Galvez-Contreras AY, Campos-Ordóñez T, Lopez-Virgen V, Gomez-Plascencia J, Ramos-Zuniga R, Gonzalez-Perez O. Growth factors as clinical biomarkers of prognosis and diagnosis in psychiatric disorders. *Cytokine Growth Factor Rev* 2016; 32: 85-96.
47. Quartini A, Pacitti F, Bersani G, Iannitelli A. From adolescent neurogenesis to schizophrenia: Opportunities, challenges and promising interventions. *Biomed Rev* 2017; 28: 66-73.
48. Dell'Omo G, Fiore M, Alleva E. Strain differences in mouse response to odours of predators. *Behav Processes* 1994; 32: 105-15.
49. Weinstock M. Prenatal stressors in rodents: effects on behavior. *Neurobiol Stress* 2017; 6: 3-13.
50. Weinstock M. Alterations induced by gestational stress in brain morphology and behaviour of the offspring. *Prog Neurobiol* 2001; 65: 427-51.
51. Maccari S, Darnaudery M, Morley-Fletcher S, Zuena AR, Cinque C, Van Reeth O. Prenatal stress and long-term consequences: implications of glucocorticoid hormones. *Neurosci Biobehav Rev* 2003; 27: 119-27.
52. Pike IL. Maternal stress and fetal responses: evolutionary perspectives on preterm delivery. *Am J Hum Biol* 2005; 17: 55-65.
53. Sampogna G, Fiorillo A, Luciano M, et al. A randomized controlled trial on the efficacy of a psychosocial behavioral intervention to improve the lifestyle of patients with severe mental disorders: study protocol. *Front Psychiatry* 2018; 9: 235.
54. Bersani G, Iannitelli A. [Legalization of cannabis: between political irresponsibility and loss of responsibility of psychiatrists]. *Riv Psichiatr* 2015; 50: 195-8.
55. Mazza M, Lucci G, Pacitti F, et al. Could schizophrenic subjects improve their social cognition abilities only with observation and imitation of social situations? *Neuropsychol Rehabil* 2010; 20: 675-703.
56. Alleva E, Francia N. Psychiatric vulnerability: suggestions from animal models and role of neurotrophins. *Neurosci Biobehav Rev* 2009; 33: 525-36.
57. Oyola MG, Handa RJ. Hypothalamic-pituitary-adrenal and hypothalamic-pituitary-gonadal axes: sex differences in regulation of stress responsivity. *Stress* 2017; 20: 476-94.
58. Gaffey AE, Bergeman CS, Clark LA, Wirth MM. Aging and the HPA axis: stress and resilience in older adults. *Neurosci Biobehav Rev* 2016; 68: 928-45.
59. Juruena MF. Early-life stress and HPA axis trigger recurrent adulthood depression. *Epilepsy Behav* 2014; 38: 148-59.
60. Jeanneteau FD, Lambert WM, Ismaili N, et al. BDNF and glucocorticoids regulate corticotrophin-releasing hormone (CRH) homeostasis in the hypothalamus. *Proc Natl Acad Sci U S A* 2012; 109: 1305-10.
61. Guest MA, Its AR, Lin CS. Isomonodromy aspects of the tt* equations of Cecotti and Vafa I. Stokes data. *Int Math Res Not* 2015; 2015: 11745-84.
62. Hua JY, Smith SJ. Neural activity and the dynamics of central nervous system development. *Nat Neurosci* 2004; 7: 327-32.
63. Angelucci F, Piermaria J, Gelfo F, et al. The effects of motor rehabilitation training on clinical symptoms and serum BDNF levels in Parkinson's disease subjects. *Can J Physiol Pharmacol* 2016; 94: 455-61.
64. Branchi I, D'Andrea I, Sietzema J, et al. Early social enrichment augments adult hippocampal BDNF levels and survival of BRDU-positive cells while increasing anxiety- and "depression"-like behavior. *J Neurosci Res* 2006; 83: 965-73.
65. Branchi I, D'Andrea I, Fiore M, Di Fausto V, Aloe L, Alleva E. Early social enrichment shapes social behavior and nerve growth factor and brain-derived neurotrophic factor levels in the adult mouse brain. *Biol Psychiatry* 2006; 60: 690-6.
66. Aloe L, Fiore M. Submandibular glands, nerve growth factor and neuroinflammatory responses in rodents. *Biomed Rev* 1998; 9: 93-9.
67. Fiore M, Moroni R, Aloe L. Removal of the submaxillary salivary glands and infection with the trematode *Schistosoma mansoni* alters exploratory behavior and pain thresholds in female mice. *Physiol Behav* 1997; 62: 399-406.
68. Fiore M, Amendola T, Triaca V, Alleva E, Aloe L. Fighting in the aged male mouse increases the expression of TrkA and TrkB in the subventricular zone and in the hippocampus. *Behav Brain Res* 2005; 157: 351-62.
69. Maestripietri D, De Simone R, Aloe L, Alleva E. Social status and nerve growth factor serum levels after agonistic encounters in mice. *Physiol Behav* 1990; 47: 161-4.
70. Bigi S, Maestripietri D, Aloe L, Alleva E. NGF decreases isola-

- tion-induced aggressive behavior, while increasing adrenal volume, in adult male mice. *Physiol Behav* 1992; 51: 337-43.
71. Fiore M, Amendola T, Triaca V, Tirassa P, Alleva E, Aloe L. Agonistic encounters in aged male mouse potentiate the expression of endogenous brain NGF and BDNF: possible implication for brain progenitor cells' activation. *Eur J Neurosci* 2003; 17: 1455-64.
 72. Spillantini MG, Aloe L, Alleva E, Desimone R, Goedert M, Levi-Montalcini R. Nerve growth-factor messenger-Rna and protein increase in hypothalamus in a mouse model of aggression. *Proc Natl Acad Sci U S A* 1989; 86: 8555-9.
 73. Yanev, Stanislav, Aloe L, Fiore M, Chaldakov GN. Neurotrophic and metabotropic potential of nerve growth factor and brain-derived neurotrophic factor: linking cardiometabolic and neuropsychiatric diseases. *World J Pharmacol* 2013; 2: 92.
 74. Ceccanti M, Inghilleri M, Attilia ML, et al. Deep TMS on alcoholics: effects on cortisolemia and dopamine pathway modulation. A pilot study. *Can J Physiol Pharmacol* 2015; 93: 283-90.
 75. Coriale G, Battagliese G, Pisciotta F, et al. Behavioral responses in people affected by alcohol use disorder and psychiatric comorbidity: correlations with addiction severity. *Ann Ist Super Sanita* 2019; 55: 131-42.
 76. Coriale G, Fiorentino D, Lauro F Di, et al. Fetal Alcohol Spectrum Disorder (FASD): neurobehavioral profile, indications for diagnosis and treatment. *Riv Psichiatr* 2013; 48: 359-69.
 77. Ciafrè S, Carito V, Tirassa P, et al. Ethanol consumption and innate neuroimmunity. *Biomed Rev* 2017; 28: 49-61.
 78. Ciafrè S, Carito V, Ferraguti G, et al. How alcohol drinking affects our genes: an epigenetic point of view. *Biochem Cell Biol* 2019; 7: 345-56.
 79. Ledda R, Battagliese G, Attilia F, et al. Drop-out, relapse and abstinence in a cohort of alcoholic people under detoxification. *Physiol Behav* 2019; 198: 67-75.
 80. Ciafrè S, Fiore M, Ceccanti M, Messina MP, Tirassa P, Carito V. Role of neuropeptide tyrosine (NPY) in ethanol addiction. *Biomed Rev* 2016; 27: 27-39.
 81. Ceccanti M, Iannitelli A, Fiore M. Italian Guidelines for the treatment of alcohol dependence. *Riv Psichiatr* 2018; 53: 105-6.
 82. Ceccanti M, Coriale G, Hamilton DA, et al. Virtual Morris task responses in individuals in an abstinence phase from alcohol. *Can J Physiol Pharmacol* 2018; 96: 128-36.
 83. Ceccanti M, Hamilton D, Coriale G, et al. Spatial learning in men undergoing alcohol detoxification. *Physiol Behav* 2015; 149: 324-30.
 84. Fein G, Torres J, Price LJ, Di Sclafani V. Cognitive performance in long-term abstinent alcoholic individuals. *Alcohol Clin Exp Res* 2006; 30: 1538-44.
 85. Ferraguti G, Ciolli P, Carito V, et al. Ethylglucuronide in the urine as a marker of alcohol consumption during pregnancy: comparison with four alcohol screening questionnaires. *Toxicol Lett* 2017; 275: 49-56.
 86. Sakata-Haga H, Fukui Y. [Effects of ethanol on the development of circadian time keeping system]. *Nihon Arukoru Yakubutsu Igakkai Zasshi* 2007; 42: 67-75.
 87. del Campo M, Jones KL. A review of the physical features of the fetal alcohol spectrum disorders. *Eur J Med Genet* 2017; 60: 55-64.
 88. Kodituwakku P, Coriale G, Fiorentino D, et al. Neurobehavioral characteristics of children with fetal alcohol spectrum disorders in communities from Italy: preliminary results. *Alcohol Clin Exp Res* 2006; 30: 1551-61.
 89. Aloe L, Tuveri MA, Guerra G, et al. Changes in human plasma nerve growth factor level after chronic alcohol consumption and withdrawal. *Alcohol Exp Res* 1996; 20: 462-5.
 90. Carito V, Ceccanti M, Cestari V, et al. Olive polyphenol effects in a mouse model of chronic ethanol addiction. *Nutrition* 2017; 33: 65-69.
 91. Carito V, Ceccanti M, Tarani L, Ferraguti G, Chaldakov GN, Fiore M. Neurotrophins' modulation by olive polyphenols. *Curr Med Chem* 2016; 23: 3189-97.
 92. De Nicolò S, Carito V, Fiore M, Laviola G. Aberrant behavioral and neurobiologic profiles in rodents exposed to ethanol or red wine early in development. *Curr Dev Disord Reports* 2014; 1: 173-80.
 93. Fiore M, Mancinelli R, Aloe L, et al. Hepatocyte growth factor, vascular endothelial growth factor, glial cell-derived neurotrophic factor and nerve growth factor are differentially affected by early chronic ethanol or red wine intake. *Toxicol Lett* 2009; 188: 208-13.
 94. Ceccanti M, Mancinelli R, Tirassa P, et al. Early exposure to ethanol or red wine and long-lasting effects in aged mice. A study on nerve growth factor, brain-derived neurotrophic factor, hepatocyte growth factor, and vascular endothelial growth factor. *Neurobiol Aging* 2012; 33: 359-67.
 95. Fiore M, Laviola G, Aloe L, di Fausto V, Mancinelli R, Ceccanti M. Early exposure to ethanol but not red wine at the same alcohol concentration induces behavioral and brain neurotrophin alterations in young and adult mice. *Neurotoxicology* 2009; 30: 59-71.
 96. Ceccanti M, De Nicolò S, Mancinelli R, et al. NGF and BDNF long-term variations in the thyroid, testis and adrenal glands of a mouse model of fetal alcohol spectrum disorders. *Ann Ist Super Sanita* 2013; 49: 383-90.
 97. Carito V, Ceccanti M, Ferraguti G, Coccorello R, Ciafrè S, Tirassa P, Fiore M. NGF and BDNF alterations by prenatal alcohol exposure. *Curr Neuropharmacol* 2019; 17: 308-17.
 98. De Simone R, Aloe L. Influence of ethanol consumption on brain nerve growth factor and its target cells in developing and adult rodents. *Ann Ist Super Sanita* 1993; 29: 179-83.
 99. Angelucci F, Fiore M, Cozzari C, Aloe L. Prenatal ethanol effects on NGF level, NPY and ChAT immunoreactivity in mouse entorhinal cortex: a preliminary study. *Neurotoxicol Teratol* 1999; 21: 415-25.
 100. Aloe L, Tirassa P. The effect of long-term alcohol intake on brain NGF-target cells of aged rats. *Alcohol* 1992; 9: 299-304.
 101. Lhullier AC, Moreira FP, da Silva RA, et al. Increased serum neurotrophin levels related to alcohol use disorder in a young population sample. *Alcohol Clin Exp Res* 2015; 39: 30-5.
 102. Ceccanti M, Coccorello R, Carito V, et al. Paternal alcohol exposure in mice alters brain NGF and BDNF and increases ethanol-elicited preference in male offspring. *Addict Biol* 2016; 21: 776-87.
 103. Miller MW, Mooney SM. Chronic exposure to ethanol alters neurotrophin content in the basal forebrain-cortex system in the mature rat: effects on autocrine-paracrine mechanisms. *J Neurobiol* 2004; 60: 490-8.
 104. Mooney SM, Miller MW. Nerve growth factor neuroprotection of ethanol-induced neuronal death in rat cerebral cortex is age dependent. *Neuroscience* 2007; 149: 372-81.
 105. Li Z, Ding M, Thiele CJ, Luo J. Ethanol inhibits brain-derived neurotrophic factor-mediated intracellular signaling and activator protein-1 activation in cerebellar granule neurons. *Neuroscience* 2004; 126: 149-62.
 106. Carito V, Ciafrè S, Tarani L, et al. TNF- α and IL-10 modulation induced by polyphenols extracted by olive pomace in a mouse model of paw inflammation. *Ann Ist Super Sanita* 2015; 51: 382-6.
 107. Aloe L, Fiore M. TNF-alpha expressed in the brain of transgenic mice lowers central tyroxine hydroxylase immunoreactivity and alters grooming behavior. *Neurosci Lett* 1997; 238: 65-8.
 108. Heberlein A, Schuster R, Kleimann A, et al. Joint effects of the epigenetic alteration of neurotrophins and cytokine signaling: a possible exploratory model of affective symptoms in alcohol-dependent patients? *Alcohol Alcohol* 2017; 52: 277-81.

Nerve growth factor in the psychiatric brain

109. Bersani G, Iannitelli A, Fiore M, Angelucci F, Aloe L. Data and hypotheses on the role of nerve growth factor and other neurotrophins in psychiatric disorders. *Med Hypotheses* 2000; 55: 199-207.
110. Stampachiachiere B, Marinova T, Velikova K, et al. Altered levels of nerve growth factor in the thymus of subjects with myasthenia gravis. *J Neuroimmunol* 2004; 146: 199-202.
111. Aloe L, Iannitelli A, Bersani G, et al. Haloperidol administration in humans lowers plasma nerve growth factor level: evidence that sedation induces opposite effects to arousal. *Neuropsychobiology* 1997; 36: 65-8.
112. Parikh V, Khan MM, Terry A, Mahadik SP. Differential effects of typical and atypical antipsychotics on nerve growth factor and choline acetyltransferase expression in the cortex and nucleus basalis of rats. *J Psychiatr Res* 2004; 38: 521-9.
113. Parnanzone S, Serrone D, Rossetti MC, et al. Alterations of cerebral white matter structure in psychosis and their clinical correlations: a systematic review of Diffusion Tensor Imaging studies. *Riv Psichiatr* 2017; 52: 49-66.
114. Raedler TJ, Knable MB, Weinberger DR. Schizophrenia as a developmental disorder of the cerebral cortex. *Curr Opin Neurobiol* 1998; 8: 157-61.
115. Bersani G, Quartini A, Iannitelli A, et al. Corpus callosum abnormalities and potential age effect in men with schizophrenia: an MRI comparative study. *Psychiatry Res* 2010; 183: 119-25.
116. Bersani G, Quartini A, Paolemili M, et al. Neurological soft signs and corpus callosum morphology in schizophrenia. *Neurosci Lett* 2011; 499: 170-4.
117. Fiore M, Dell'Omo G, Alleva E, Lipp HP. A comparison of behavioural effects of prenatally administered oxazepam in mice exposed to open-fields in the laboratory and the real world. *Psychopharmacol* 1995; 122: 72-7.
118. Bersani G, Quartini A, Manuali G, et al. Influence of obstetric complication severity on brain morphology in schizophrenia: an MR study. *Neuroradiology* 2009; 51: 363-71.
119. Rocca P, Galderisi S, Rossi A, et al. Disorganization and real-world functioning in schizophrenia: Results from the multicenter study of the Italian Network for Research on Psychoses. *Schizophr Res* 2018; 201: 105-12.
120. Galderisi S, Rucci P, Kirkpatrick B, et al. Interplay among psychopathologic variables, personal resources, context-related factors, and real-life functioning in individuals with schizophrenia a network analysis. *JAMA Psychiatry* 2018; 75: 396-404.
121. Millar JK, James K, Brandon NJ, Thomson PA. DISC1 and DISC2: discovering and dissecting molecular mechanisms underlying psychiatric illness. *Ann Med* 2004; 36: 367-78.
122. Mackie S, Millar JK, Porteous DJ. Role of DISC1 in neural development and schizophrenia. *Curr Opin Neurobiol* 2007; 17: 95-102.
123. Tomoda T, Hikida T, Sakurai T. Role of DISC1 in neuronal trafficking and its implication in neuropsychiatric manifestation and neurotherapeutics. *Neurotherapeutics* 2017; 14: 623-9.
124. Dahoun T, Trossbach SV, Brandon NJ, Korth C, Howes OD. The impact of Disrupted-in-Schizophrenia 1 (DISC1) on the dopaminergic system: a systematic review. *Transl Psychiatry* 2017; 7: e1015.
125. Matsuzaki S, Tohyama M. Molecular mechanism of schizophrenia with reference to disrupted-in-schizophrenia 1 (DISC1). *Neurochem Int* 2007; 51: 165-72.
126. Iwabuchi SJ, Peng D, Fang Y, et al. Alterations in effective connectivity anchored on the insula in major depressive disorder. *Eur Neuropsychopharmacol* 2014; 24: 1784-92.
127. Tanti A, Belzung C. Neurogenesis along the septo-temporal axis of the hippocampus: are depression and the action of antidepressants region-specific? *Neuroscience* 2013; 252: 234-52.
128. Lang UE, Borgwardt S. Molecular mechanisms of depression: perspectives on new treatment strategies. *Cell Physiol Biochem* 2013; 31: 761-77.
129. Tirassa P, Iannitelli A, Sornelli F, et al. Daily serum and salivary BDNF levels correlate with morning-evening personality type in women and are affected by light therapy. *Riv Psichiatr* 2012; 47: 527-34.
130. Wiener CD, de Mello Ferreira S, Pedrotti Moreira F, et al. Serum levels of nerve growth factor (NGF) in patients with major depression disorder and suicide risk. *J Affect Disord* 2015; 184: 245-8.
131. Banerjee R, Ghosh AK, Ghosh B, Bhattacharyya S, Mondal AC. Decreased mRNA and protein expression of BDNF, NGF, and their receptors in the hippocampus from suicide: an analysis in human postmortem brain. *Clin Med Insights Pathol* 2013; 6: 1-11.
132. Mandolesi G, Bullitta S, Fresegna D, et al. Interferon-gamma causes mood abnormalities by altering cannabinoid CB1 receptor function in the mouse striatum. *Neurobiol Dis* 2017; 108: 45-53.
133. Campos AC, Vaz GN, Saito VM, Teixeira AL. Further evidence for the role of interferon-gamma on anxiety- and depressive-like behaviors: involvement of hippocampal neurogenesis and NGF production. *Neurosci Lett* 2014; 578: 100-5.
134. McGeary JE, Gurel V, Knopik VS, Spaulding J, McMichael J. Effects of nerve growth factor (NGF), fluoxetine, and amitriptyline on gene expression profiles in rat brain. *Neuropeptides* 2011; 45: 317-22.
135. Xu C-J, Wang J-L, Jin W-L. The emerging therapeutic role of NGF in Alzheimer's disease. *Neurochem Res* 2016; 41: 1211-8.
136. Angelucci F, Gelfo F, Fiore M, et al. The effect of neuropeptide Y on cell survival and neurotrophin expression in in-vitro models of Alzheimer's disease. *Can J Physiol Pharmacol* 2014; 92: 621-30.
137. Scott SA, Mufson EJ, Weingartner JA, Skau KA, Crutcher KA. Nerve growth factor in Alzheimer's disease: increased levels throughout the brain coupled with declines in nucleus basalis. *J Neurosci* 1995; 15: 6213-21.
138. Arendt T. Impairment in memory function and neurodegenerative changes in the cholinergic basal forebrain system induced by chronic intake of ethanol. *Cell Anim Model Aging Dement Res* 1994; 44: 173-87.
139. Arendt T, Bruckner MK, Bigl V, Marcova L. Dendritic reorganisation in the basal forebrain under degenerative conditions and its defects in Alzheimer's disease. III. The basal forebrain compared with other subcortical areas. *J Comp Neurol* 1995; 351: 223-46.
140. Skaper SD. Neurotrophic factors: an overview. *Methods Mol Biol* 2018; 1727: 1-17.
141. Budni J, Bellettini-Santos T, Mina F, Garcez ML, Zugno AI. The involvement of BDNF, NGF and GDNF in aging and Alzheimer's disease. *Aging Dis* 2015; 6: 331-41.
142. Huang EJ, Reichardt LF. Trk receptors: roles in neuronal signal transduction. *Annu Rev Biochem* 2003; 72: 609-42.
143. Guerios SD, Wang Z-Y, Boldon K, Bushman W, Bjorling DE. Blockade of NGF and trk receptors inhibits increased peripheral mechanical sensitivity accompanying cystitis in rats. *AJP Regul Integr Comp Physiol* 2008; 295: R111-22.
144. Triaca V. Homage to Rita Levi-Montalcini. Molecular mechanisms of Alzheimer's disease: NGF modulation of APP processing. *Adipobiology* 2013; 5: 7-18.
145. Mufson EJ, He B, Nadeem M, et al. Hippocampal proNGF signaling pathways and beta-amyloid levels in mild cognitive impairment and Alzheimer disease. *J Neuropathol Exp Neurol* 2012; 71: 1018-29.
146. Calissano P, Matrone C, Amadoro G. Nerve growth factor as a paradigm of neurotrophins related to Alzheimer's disease. *Dev Neurobiol* 2010; 70: 372-83.
147. Ruberti F, Capsoni S, Comparini A, et al. Phenotypic knockout of nerve growth factor in adult transgenic mice reveals severe

- deficits in basal forebrain cholinergic neurons, cell death in the spleen, and skeletal muscle dystrophy. *J Neurosci* 2000; 20: 2589-601.
148. Triaca V, Sposato V, Bolasco G, et al. NGF controls APP cleavage by downregulating APP phosphorylation at Thr668: relevance for Alzheimer's disease. *Aging Cell* 2016; 15: 661-72.
 149. Terry AVJ, Kutianawalla A, Pillai A. Age-dependent alterations in nerve growth factor (NGF)-related proteins, sortilin, and learning and memory in rats. *Physiol Behav* 2011; 102: 149-57.
 150. Canu N, Amadoro G, Triaca V, et al. The intersection of NGF/TrkA signaling and amyloid precursor protein processing in Alzheimer's disease neuropathology. *Int J Mol Sci* 2017; 18: pii: E1319.
 151. Yegla B, Parikh V. Effects of sustained pro NGF blockade on attentional capacities in aged rats with compromised cholinergic system. *Neuroscience* 2014; 261: 118-32.
 152. Parikh V, Howe WM, Welchko RM, et al. Diminished trkA receptor signaling reveals cholinergic-attentional vulnerability of aging. *Eur J Neurosci* 2013; 37: 278-93.
 153. Counts SE, Mufson EJ. The role of nerve growth factor receptors in cholinergic basal forebrain degeneration in prodromal Alzheimer disease. *J Neuropathol Exp Neurol* 2005; 64: 263-72.
 154. Matrone C, Di Luzio A, Meli G, et al. Activation of the amyloidogenic route by NGF deprivation induces apoptotic death in PC12 cells. *J Alzheimers Dis* 2008; 13: 81-96.
 155. Latina V, Caioli S, Zona C, Ciotti MT, Amadoro G, Calissano P. Impaired NGF/TrkA signaling causes early AD-Linked presynaptic dysfunction in cholinergic primary neurons. *Front Cell Neurosci* 2017; 11: 68.
 156. O'Brien RJ, Wong PC. Amyloid precursor protein processing and Alzheimer's disease. *Annu Rev Neurosci* 2011; 34: 185-204.
 157. Tamayev R, Zhou D, D'Adamo L. The interactome of the amyloid beta precursor protein family members is shaped by phosphorylation of their intracellular domains. *Mol Neurodegener* 2009; 4: 28.
 158. Lee M-S, Kao S-C, Lemere CA, et al. APP processing is regulated by cytoplasmic phosphorylation. *J Cell Biol* 2003; 163: 83-95.
 159. Chang K-A, Kim H-S, Ha T-Y, et al. Phosphorylation of amyloid precursor protein (APP) at Thr668 regulates the nuclear translocation of the APP intracellular domain and induces neurodegeneration. *Mol Cell Biol* 2006; 26: 4327-38.
 160. Bloom GS. Amyloid-beta and tau: the trigger and bullet in Alzheimer disease pathogenesis. *JAMA Neurol* 2014; 71: 505-8.
 161. Ribe EM, Perez M, Puig B, et al. Accelerated amyloid deposition, neurofibrillary degeneration and neuronal loss in double mutant APP/tau transgenic mice. *Neurobiol Dis* 2005; 20: 814-22.
 162. Amadoro G, Corsetti V, Ciotti MT, et al. Endogenous Aβ causes cell death via early tau hyperphosphorylation. *Neurobiol Aging* 2011; 32: 969-90.
 163. Carter C. Alzheimer's disease: APP, Gamma Secretase, APOE, CLU, CR1, PICALM, ABCA7, BIN1, CD2AP, CD33, EPHA1, and MS4A2, and their relationships with Herpes Simplex, C. Pneumoniae, other suspect pathogens, and the immune system. *Int J Alzheimers Dis* 2011; 2011: 501862.
 164. Corsetti V, Amadoro G, Gentile A, et al. Identification of a caspase-derived N-terminal tau fragment in cellular and animal Alzheimer's disease models. *Mol Cell Neurosci* 2008; 38: 381-92.
 165. Taurines R, Schwenck C, Westerwald E, Sachse M, Siniatchkin M, Freitag C. ADHD and autism: differential diagnosis or overlapping traits? A selective review. *Atten Defic Hyperact Disord* 2012; 4: 115-39.
 166. Khanzada NS, Butler MG, Manzardo AM. GeneAnalytics pathway analysis and genetic overlap among autism spectrum disorder, bipolar disorder and schizophrenia. *Int J Mol Sci* 2017; 18: pii: E527.
 167. Stamova BS, Tian Y, Nordahl CW, et al. Evidence for differential alternative splicing in blood of young boys with autism spectrum disorders. *Mol Autism* 2013; 4: 30.
 168. Lu AT-H, Yoon J, Geschwind DH, Cantor RM. QTL replication and targeted association highlight the nerve growth factor gene for nonverbal communication deficits in autism spectrum disorders. *Mol Psychiatry* 2013; 18: 226-35.
 169. Rassi AJ, Rassi A, Marcondes de Rezende J. American trypanosomiasis (Chagas disease). *Infect Dis Clin North Am* 2012; 26: 275-91.
 170. Rassi AJ, Rassi A, Marin-Neto JA. Chagas disease. *Lancet* 2010; 375: 1388-402.
 171. Maudlin I, Holmes PH, Miles MA (eds). *The trypanosomiasis*. Wallingford, UK: CABI Publishing, 2004.
 172. Chuenkova MV, Pereira MA. The T. cruzi trans-sialidase induces PC12 cell differentiation via MAPK/ERK pathway. *Neuroreport* 2001; 12: 3715-8.
 173. Hoff R, Teixeira RS, Carvalho JS, Mott KE. Trypanosoma cruzi in the cerebrospinal fluid during the acute stage of Chagas' disease. *N Engl J Med* 1978; 298: 604-6.
 174. De Souza MM, Andrade SG, Barbosa AA, Santos RTM, Alves VAF, Andrade ZA. Trypanosoma cruzi strains and autonomic nervous system pathology in experimental Chagas disease. *Mem Inst Oswaldo Cruz* 1996; 91: 217-24.
 175. Tafuri WL. Pathogenesis of lesions of the autonomic nervous system of the mouse in experimental acute Chagas' disease. Light and electron microscope studies. *Am J Trop Med Hyg* 1970; 19: 405-17.
 176. Molina HA, Cardoni RL, Rimoldi MT. The neuromuscular pathology of experimental Chagas' disease. *J Neurol Sci* 1987; 81: 287-300.
 177. Said G, Joskowicz M, Barreira AA, Eisen H. Neuropathy associated with experimental Chagas' disease. *Ann Neurol* 1985; 18: 676-83.
 178. Bocchi EA, Bestetti RB, Scanavacca MI, Cunha Neto E, Issa VS. Chronic Chagas heart disease management: from etiology to cardiomyopathy treatment. *J Am Coll Cardiol* 2017; 70: 1510-24.
 179. Malik LH, Singh GD, Amsterdam EA. Chagas heart disease: an update. *Am J Med* 2015; 128: 1251.e7-9.
 180. Chuenkova MV, Pereiraperrin M. Neurodegeneration and neuroregeneration in Chagas disease. *Adv Parasitol* 2011; 76: 195-233.
 181. Chuenkova MV, Pereira Perrin M. Chagas' disease parasite promotes neuron survival and differentiation through TrkA nerve growth factor receptor. *J Neurochem* 2004; 91: 385-94.
 182. Palin MS, Mathew R, Towns G. Spinal neuroschistosomiasis. *Br J Neurosurg* 2015; 29: 582-4.
 183. Carod-Artal FJ. Neuroschistosomiasis. *Expert Rev Anti Infect Ther* 2010; 8: 1307-18.
 184. Ferrari TCA, Gazzinelli G, Correa-Oliveira R. Immune response and pathogenesis of neuroschistosomiasis mansoni. *Acta Trop* 2008; 108: 83-8.
 185. Nascimento-Carvalho CM, Moreno-Carvalho OA. Neuroschistosomiasis due to Schistosoma mansoni: a review of pathogenesis, clinical syndromes and diagnostic approaches. *Rev Inst Med Trop Sao Paulo* 2005; 47: 179-84.
 186. Pittella JEH. Neuroschistosomiasis. *Brain Pathol* 1997; 7: 649-62.
 187. Varilek GW, Weinstock JV, Pantazis NJ. Isolated hepatic granulomas from mice infected with Schistosoma mansoni contain nerve growth factor. *Infect Immun* 1991; 59: 4443-9.
 188. Aloe L, Moroni R, Mollinari C, Tirassa P. Schistosoma mansoni infection enhances the levels of NGF in the liver and hypothalamus of mice. *Neuroreport* 1994; 5: 1030-2.

Nerve growth factor in the psychiatric brain

189. Aloe L, Moroni R, Fiore M, Angelucci F. Chronic parasite infection in mice induces brain granulomas and differentially alters brain nerve growth factor levels and thermal responses in paws. *Acta Neuropathol* 1996; 92: 300-5.
190. Aloe L, Moroni R, Angelucci F, Fiore M. Role of TNF- α but not NGF in murine hyperalgesia induced by parasitic infection. *Psychopharmacology* 1997; 134: 287-92.
191. Fiore M, Carere C, Moroni R, Aloe L. Passive avoidance response in mice infected with *Schistosoma mansoni*. *Physiol Behav* 2002; 75: 449-54.
192. Fiore M, Aloe L. Neuroinflammatory implication of *Schistosoma mansoni* infection in the mouse. *Arch Physiol Biochem* 2001; 109: 361-4.
193. Fiore M, Moroni R, Alleva E, Aloe L. *Schistosoma mansoni*: influence of infection on mouse behavior. *Exp Parasitol* 1996; 83: 46-54.
194. Aloe L, Fiore M. Neuroinflammatory implications of *Schistosoma mansoni* infection: new information from the mouse model. *Parasitol Today* 1998; 14: 314-8.
195. Fiore M, Alleva E, Moroni R, Aloe L. Infection with *Schistosoma mansoni* in mice induces changes in nociception and exploratory behavior. *Physiol Behav* 1998; 65: 347-53.
196. Tuszynski MH, Blesch A. Nerve growth factor: from animal models of cholinergic neuronal degeneration to gene therapy in Alzheimer's disease. *Prog Brain Res* 2004; 146: 441-9.
197. Tuszynski MH, Thal L, Pay M, et al. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. *Nat Med* 2005; 11: 551-5.
198. Malkki H. Alzheimer disease: NGF gene therapy activates neurons in the AD patient brain. *Nat Rev Neurol* 2015; 11: 548.
199. Karami A, Eyjolfsson H, Vijayaraghavan S, et al. Changes in CSF cholinergic biomarkers in response to cell therapy with NGF in patients with Alzheimer's disease. *Alzheimers Dement* 2015; 11: 1316-28.
200. Bersani G, Quartini A, Zullo D, Iannitelli A. Potential neuroprotective effect of lithium in bipolar patients evaluated by neuropsychological assessment: preliminary results. *Hum Psychopharmacol* 2016; 31: 19-28.
201. Tuszynski MH, Yang JH, Barba D, et al. Nerve growth factor gene therapy activation of neuronal responses in Alzheimer disease. *JAMA Neurol* 2015; 72: 1139-47.
202. Parikh V, Evans DR, Khan MM, Mahadik SP. Nerve growth factor in never-medicated first-episode psychotic and medicated chronic schizophrenic patients: possible implications for treatment outcome. *Schizophr Res* 2003; 60: 117-23.
203. Machado-Vieira R, Manji HK, Zarate CAJ. The role of lithium in the treatment of bipolar disorder: convergent evidence for neurotrophic effects as a unifying hypothesis. *Bipolar Disord* 2009; 11 Suppl 2: 92-109.
204. Quartini A, Iannitelli A, Bersani G. Lithium: from mood stabilizer to putative cognitive enhancer. *Neural Regen Res* 2016; 11: 1234-5.
205. Gorbachevskaya N, Bashina V, Gratchev V, Iznak A. Cerebrolysin therapy in Rett syndrome: clinical and EEG mapping study. *Brain Dev* 2001; 23: S90-3.
206. Du Y, Wu H-T, Qin X-Y, et al. Postmortem brain, cerebrospinal fluid, and blood neurotrophic factor levels in Alzheimer's disease: a systematic review and meta-analysis. *J Mol Neurosci* 2018; 65: 289-300.
207. Mohammadi A, Rashidi E, Amooeian VG. Brain, blood, cerebrospinal fluid, and serum biomarkers in schizophrenia. *Psychiatry Res* 2018; 265: 25-38.